3billion, Macrogen Japan Sign MOU... Entering Japanese Rare Disease Diagnosis Market

Three Billion announced on the 23rd that it has signed an MOU with Macrogen Japan to enter the Japanese rare disease diagnosis market.

Through the MOU, Three Billion is expected to effectively introduce its rare disease diagnosis and analysis services to the Japanese market by utilizing Macrogen Japan's local infrastructure. It is anticipated to lead innovation in rare disease diagnosis in Japan, the most advanced medical market in East Asia with a population of over 120 million.

Geum Chang-won, CEO of Three Billion, explained, "This will serve as a stepping stone for entering the Japanese rare disease diagnosis market," and added, "By leveraging Macrogen Japan's infrastructure, we will reach more patients with our advanced rare disease diagnosis and analysis services."

Three Billion's AI-based rare disease diagnosis technology can interpret the pathogenicity of each of the patient's 100,000 genetic variants with 99.4% accuracy within 5 minutes. It can identify the causative genetic variants with 98.1% accuracy based on the top-5 criteria. Based on this technological capability, it is expected to provide fast and precise diagnostic services to Japanese medical professionals.

Three Billion has accumulated over 70,000 rare disease data cases through cooperation with more than 700 institutions in over 90 countries. It was listed on the KOSDAQ market on the 14th of last month. Overseas sales account for nearly 70%, demonstrating rapid global expansion.